Asia Pacific Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Technology ; Application, and Country

Asia Pacific Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Technology ; Application, and Country

  • September 2020 •
  • 147 pages •
  • Report ID: 5978829 •
  • Format: PDF
The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020-2027.

The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge in need for non-invasive drug delivery solutions, increasing investments in R&D for pharmaceutical companies. However, high expense involved in the development of drug delivery systems is expected to obstruct the growth of the market to a certain extent during the forecast years.

Liposomes are small sphere-shaped artificial vesicles synthesized from cholesterol and phospholipids. They have multiple layers and a diameter range of 0.01 to 5.0 um. They also have hydrophilic and hydrophobic properties which help liposomes to encapsulate hydrophobic and hydrophilic drugs to be delivered to targeted body site. Liposomes provide an assured system for targeted drug delivery and thereby is the factor influencing the Liposome Drug Delivery market size growth. Liposomes are widely used for enclosing all types of drug molecules such as acyclovir, chloroquine diphosphate, paclitaxel, tropicamide, and cyclosporine. Liposomes are used as a drug carrier for drug therapy for many diseases since they are biodegradable and biocompatible. Also, they have many therapeutic properties like anticancer drugs, genetic materials, proteins, vaccines, macromolecules, and thus can be encapsulated in liposomes.

Research and development (R&D) in liposomal drug delivery systems are increasing across the world due to the increasing prevalence of chronic disease.Drug delivery is the process of dispensing a pharmaceutical compound to attain a therapeutic effect in humans.

Liposomal drug delivery offers multiple advantages such as better pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity making these delivery systems ideal for patients suffering from various chronic conditions.

Death among the population worldwide has increased due to cancer.The targeted drug delivery system delivers the drug in a controlled manner at a preselected bio site.

Nanotechnology-based delivery systems are making a crucial impact on cancer treatment, and the polymers play a key role in the development of Nano particulate carriers for cancer therapy.Some of the major technological advantages involved in the nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of the drug, and many more.

The liposomal carriers used in nanotechnology drug delivery systems are likely to experience rapid adoption, which in turn is propelling the market growth.

As per the data provided by, European Society for Medical Oncology, China estimated there were 4.3 million new cancer cases and more than 2.8 million cancer deaths in China in 2015, with lung cancer the most common cancer and the leading cause of cancer death. With high incidences and mortality, cancer is the leading cause of death in China and is a major public health problem. Further, Conference Series LLC Ltd is going to host Pharmaceutics & Novel Drug Delivery Summit China, which is going to be held during November 16-17, 2020, in Shanghai, China, for the adoption of novel drug delivery system. For instance, Lipusu (chemotherapy treatment of certain types of cancer) was the most popular pharmaceutical product for cancer treatment in China in the first half of 2018, as well as the most popular paclitaxel product in China in the first half of 2018 with a market share of approximately 34.8%.

Diabetes is one of the leading life-threatening chronic diseases with no functional cure.As there is a significant increase in diabetes cases across the world, it is resulting in life-changing complications among the population.

Exogenous insulin is usually administered through a subcutaneous route of administration for diabetes management. However, the recent attention towards insulin-coated liposomal carriers facilitating oral insulin intake and activating the target drug delivery action, which on the other hand is propelling the growth of the liposome drug delivery market over the coming years.

Based on product, the liposome drug delivery market is segmented into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, others. The liposomal doxorubicin segment held the largest share of the market in 2019, whereas the liposomal amphotericin B segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on technology, the liposome drug delivery market has been segmented into stealth liposome technology, non-PEGylated liposome technology, depofoam liposome technology. The stealth liposome technology segment held the largest share of the market in 2019, and continued to register the highest CAGR in the market during the forecast period.

Based on application, the liposome drug delivery market has been segmented into fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. The cancer therapy segment held the largest share of the market in 2019, and continued to register the highest CAGR in the market during the forecast period.

Some of the major primary and secondary sources for liposome drug delivery market included in the report are National Cancer Institute (NCI), Chinese Society of Clinical Oncology (CSCO) Guidelines, and others.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.